Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.

Giaginis C, Tsoukalas N, Bournakis E, Alexandrou P, Kavantzas N, Patsouris E, Theocharis S.

BMC Clin Pathol. 2014 Feb 4;14(1):8. doi: 10.1186/1472-6890-14-8.

2.

Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma.

Giaginis C, Tsourouflis G, Zizi-Serbetzoglou A, Kouraklis G, Chatzopoulou E, Dimakopoulou K, Theocharis SE.

Pathol Oncol Res. 2010 Jun;16(2):267-76. doi: 10.1007/s12253-009-9221-6. Epub 2009 Dec 1.

PMID:
19949912
3.

Ephrin receptor (Eph) -A1, -A2, -A4 and -A7 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.

Theocharis S, Klijanienko J, Giaginis C, Alexandrou P, Patsouris E, Sastre-Garau X.

Pathol Oncol Res. 2014 Apr;20(2):277-84. doi: 10.1007/s12253-013-9692-3. Epub 2013 Sep 11.

PMID:
24022400
4.

Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human non-small-cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.

Giaginis C, Alexandrou P, Tsoukalas N, Sfiniadakis I, Kavantzas N, Agapitos E, Patsouris E, Theocharis S.

Tumour Biol. 2015 Jan;36(1):315-27. doi: 10.1007/s13277-014-2637-y. Epub 2014 Sep 25.

PMID:
25252849
5.

Effects of altered ephrin-A5 and EphA4/EphA7 expression on tumor growth in a medulloblastoma mouse model.

Bhatia S, Hirsch K, Baig NA, Rodriguez O, Timofeeva O, Kavanagh K, Lee YC, Wang XJ, Albanese C, Karam SD.

J Hematol Oncol. 2015 Sep 7;8:105. doi: 10.1186/s13045-015-0202-9.

6.

Eph-A2 and Eph-A4 expression in human benign and malignant thyroid lesions: an immunohistochemical study.

Karidis NP, Giaginis C, Tsourouflis G, Alexandrou P, Delladetsima I, Theocharis S.

Med Sci Monit. 2011 Sep;17(9):BR257-65.

7.

Gradients of Eph-A6 expression in primate retina suggest roles in both vascular and axon guidance.

Kozulin P, Natoli R, Madigan MC, O'Brien KM, Provis JM.

Mol Vis. 2009 Dec 9;15:2649-62.

8.

Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival.

Herath NI, Spanevello MD, Sabesan S, Newton T, Cummings M, Duffy S, Lincoln D, Boyle G, Parsons PG, Boyd AW.

BMC Cancer. 2006 Jun 1;6:144.

9.

Eph-ephrin A system regulates human choriocarcinoma-derived JEG-3 cell invasion.

Fujiwara H, Nishioka Y, Matsumoto H, Suginami K, Horie A, Tani H, Matsumura N, Baba T, Sato Y, Araki Y, Konishi I.

Int J Gynecol Cancer. 2013 Mar;23(3):576-82. doi: 10.1097/IGC.0b013e3182849e36.

PMID:
23429488
10.

Expression of ephrin-A ligands and EphA receptors in the developing mouse tooth and its supporting tissues.

Luukko K, Løes S, Kvinnsland IH, Kettunen P.

Cell Tissue Res. 2005 Jan;319(1):143-52. Epub 2004 Oct 27.

PMID:
15517401
11.

Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients.

Giaginis C, Sampani A, Kotta-Loizou I, Giannopoulou I, Danas E, Politi E, Tsourouflis G, Kouraklis G, Patsouris E, Keramopoulos A, Nakopoulou L, Theocharis S.

Pathol Oncol Res. 2017 Aug 14. doi: 10.1007/s12253-017-0288-1. [Epub ahead of print]

12.

Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.

Ishikawa M, Miyahara R, Sonobe M, Horiuchi M, Mennju T, Nakayama E, Kobayashi M, Kikuchi R, Kitamura J, Imamura N, Huang CL, Date H.

Lung Cancer. 2012 Jun;76(3):431-8. doi: 10.1016/j.lungcan.2011.12.004. Epub 2012 Jan 10.

PMID:
22236865
13.

Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma.

Toma MI, Erdmann K, Diezel M, Meinhardt M, Zastrow S, Fuessel S, Wirth MP, Baretton GB.

PLoS One. 2014 Jul 15;9(7):e102262. doi: 10.1371/journal.pone.0102262. eCollection 2014.

14.
15.

Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer.

Rud AK, Lund-Iversen M, Berge G, Brustugun OT, Solberg SK, Mælandsmo GM, Boye K.

BMC Cancer. 2012 Aug 1;12:333.

16.
17.

Parcellation of the thalamus into distinct nuclei reflects EphA expression and function.

Lehigh KM, Leonard CE, Baranoski J, Donoghue MJ.

Gene Expr Patterns. 2013 Dec;13(8):454-63. doi: 10.1016/j.gep.2013.08.002. Epub 2013 Sep 10.

18.

Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.

Saintigny P, Peng S, Zhang L, Sen B, Wistuba II, Lippman SM, Girard L, Minna JD, Heymach JV, Johnson FM.

Mol Cancer Ther. 2012 Sep;11(9):2021-32. doi: 10.1158/1535-7163.MCT-12-0030. Epub 2012 Jul 17.

19.

Elevated Farnesoid X Receptor (FXR) and Retinoid X Receptors (RXRs) expression is associated with less tumor aggressiveness and favourable prognosis in patients with pancreatic adenocarcinoma.

Giaginis C, Koutsounas I, Alexandrou P, Zizi-Serbetzoglou A, Patsouris E, Kouraklis G, Theocharis S.

Neoplasma. 2015;62(2):332-41. doi: 10.4149/neo_2015_040.

PMID:
25591600
20.

Erythropoietin-Producing Hepatocellular A1 is an Independent Prognostic Factor for Gastric Cancer.

Nakagawa M, Inokuchi M, Takagi Y, Kato K, Sugita H, Otsuki S, Kojima K, Uetake H, Sugihara K.

Ann Surg Oncol. 2015 Jul;22(7):2329-35. doi: 10.1245/s10434-014-4231-3. Epub 2014 Nov 13.

PMID:
25391265

Supplemental Content

Support Center